158 related articles for article (PubMed ID: 20844869)
21. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
Rawal B; Deane BR
Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
[TBL] [Abstract][Full Text] [Related]
22. Availability and Use of Shared Data From Cardiometabolic Clinical Trials.
Vaduganathan M; Nagarur A; Qamar A; Patel RB; Navar AM; Peterson ED; Bhatt DL; Fonarow GC; Yancy CW; Butler J
Circulation; 2018 Feb; 137(9):938-947. PubMed ID: 29133600
[TBL] [Abstract][Full Text] [Related]
23. Outcome reporting among drug trials registered in ClinicalTrials.gov.
Bourgeois FT; Murthy S; Mandl KD
Ann Intern Med; 2010 Aug; 153(3):158-66. PubMed ID: 20679560
[TBL] [Abstract][Full Text] [Related]
24. Discontinuation and non-publication of neurodegenerative disease trials: a cross-sectional analysis.
Stefaniak JD; Lam TCH; Sim NE; Al-Shahi Salman R; Breen DP
Eur J Neurol; 2017 Aug; 24(8):1071-1076. PubMed ID: 28636179
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
26. Publication bias in the anesthesiology literature.
De Oliveira GS; Chang R; Kendall MC; Fitzgerald PC; McCarthy RJ
Anesth Analg; 2012 May; 114(5):1042-8. PubMed ID: 22344237
[TBL] [Abstract][Full Text] [Related]
27. Bone pain from granulocyte colony stimulating factor: does clinical trial sponsorship by a pharmaceutical company influence its reporting?
Aldairy Y; Nguyen PL; Jatoi A
Eur J Cancer Care (Engl); 2011 Jan; 20(1):72-6. PubMed ID: 19708947
[TBL] [Abstract][Full Text] [Related]
28. Non-publication and publication bias in reproductive medicine: a cohort analysis.
Lensen S; Jordan V; Showell M; Showell E; Shen V; Venetis C; Farquhar C
Hum Reprod; 2017 Aug; 32(8):1658-1666. PubMed ID: 28854591
[TBL] [Abstract][Full Text] [Related]
29. Discontinuation and non-publication of clinical trials in cardiovascular medicine.
Roddick AJ; Chan FTS; Stefaniak JD; Zheng SL
Int J Cardiol; 2017 Oct; 244():309-315. PubMed ID: 28622947
[TBL] [Abstract][Full Text] [Related]
30. Publication and non-publication of drug trial results: a 10-year cohort of trials in Norwegian general practice.
Brænd AM; Straand J; Jakobsen RB; Klovning A
BMJ Open; 2016 Apr; 6(4):e010535. PubMed ID: 27067893
[TBL] [Abstract][Full Text] [Related]
31. Public availability of results of trials assessing cancer drugs in the United States.
Nguyen TA; Dechartres A; Belgherbi S; Ravaud P
J Clin Oncol; 2013 Aug; 31(24):2998-3003. PubMed ID: 23878298
[TBL] [Abstract][Full Text] [Related]
32. Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study.
Jones CW; Misemer BS; Platts-Mills TF; Ahn R; Woodbridge A; Abraham A; Saba S; Korenstein D; Madden E; Keyhani S
BMJ Open; 2018 Feb; 8(2):e019831. PubMed ID: 29439079
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.
Bero L; Oostvogel F; Bacchetti P; Lee K
PLoS Med; 2007 Jun; 4(6):e184. PubMed ID: 17550302
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
Rawal B; Deane BR
Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
[TBL] [Abstract][Full Text] [Related]
35. An analysis of the clinical development of drugs in Norway for the year 2000: the completion of research and publication of results.
Hole OP; Nitter-Hauge S; Cederkvist HR; Winther FO
Eur J Clin Pharmacol; 2009 Mar; 65(3):315-8. PubMed ID: 19104790
[TBL] [Abstract][Full Text] [Related]
36. Study design, result posting, and publication of late-stage cardiovascular trials.
Kapelios CJ; Naci H; Vardas PE; Mossialos E
Eur Heart J Qual Care Clin Outcomes; 2022 May; 8(3):277-288. PubMed ID: 33098422
[TBL] [Abstract][Full Text] [Related]
37. Impact of Funding Source on Clinical Trial Results Including Cardiovascular Outcome Trials.
Riaz H; Raza S; Khan MS; Riaz IB; Krasuski RA
Am J Cardiol; 2015 Dec; 116(12):1944-7. PubMed ID: 26611124
[TBL] [Abstract][Full Text] [Related]
38. Non-publication and delayed publication of randomized trials on vaccines: survey.
Manzoli L; Flacco ME; D'Addario M; Capasso L; De Vito C; Marzuillo C; Villari P; Ioannidis JP
BMJ; 2014 May; 348():g3058. PubMed ID: 24838102
[TBL] [Abstract][Full Text] [Related]
39. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?
Chan JK; Ueda SM; Sugiyama VE; Stave CD; Shin JY; Monk BJ; Sikic BI; Osann K; Kapp DS
J Clin Oncol; 2008 Mar; 26(9):1511-8. PubMed ID: 18285603
[TBL] [Abstract][Full Text] [Related]
40. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis.
Etter JF; Burri M; Stapleton J
Addiction; 2007 May; 102(5):815-22. PubMed ID: 17493109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
